Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).

by Melanie Gentil, Patricia Hugues, Christophe Desterke, Gladys Telliam, Ivan Sloma, Lucas E B Souza, Seda Baykal, Jerome Artus, Frank Griscelli, Agnes Guerci, Hyacinthe Johnson-Ansah, Adlen Foudi, Annelise Bennaceur-Griscelli, Ali G Turhan
Published 2018-01-01